Jordan Ellis
Ertapenem is a carbapenem antibiotic used to treat bacterial infections. It is available as an injection for intravenous or intramuscular use in adults and pediatric patients. While Medicare prescription drug plans typically list ertapenem on Tier 4 of their formulary, it is not clear how prevalent this is across hospitals. Various studies have examined the impact of adding ertapenem to hospital formularies, with some finding it to be an effective antimicrobial management tool that reduces the usage of other broad-spectrum antibiotics. However, there are concerns about the widespread use of ertapenem promoting cross-resistance to other carbapenems. The addition of ertapenem to a hospital formulary should be carefully considered, taking into account potential benefits and drawbacks.
| Characteristics | Values |
|---|---|
| Ertapenem usage | Used to treat moderate to severe bacterial infections |
| Effect on hospitals' antimicrobial usage | Adding ertapenem to the formulary resulted in a decrease in the usage of other broad-spectrum antibiotics |
| Effect on hospitals' antimicrobial susceptibility | Adding ertapenem to the formulary was associated with an increase in susceptibility to other broad-spectrum antibiotics |
| Medicare prescription drug plans | Ertapenem is typically listed on Tier 4 of their formulary |
Explore related products
What You'll Learn
- Ertapenem is a carbapenem antibiotic used to treat bacterial infections
- It is available as an injection for intravenous or intramuscular use in adults and children
- Common adverse reactions include diarrhoea, nausea, headaches, and infused vein complications
- It is listed on Tier 4 of the Medicare prescription drug formulary, which can impact affordability
- Its usage may promote cross-resistance to other carbapenems, so caution is advised
Ertapenem is a carbapenem antibiotic used to treat bacterial infections
Ertapenem is available as an injection for intravenous or intramuscular administration and is typically given once daily. It is generally well-tolerated by patients, with most adverse events being mild to moderate. The most common side effects include diarrhea, nausea, headache, and infused vein complications. However, it can also cause more serious reactions, such as seizures, central nervous system adverse effects, and Clostridioides difficile-associated diarrhea.
Ertapenem is a valuable option for treating bacterial infections, particularly in patients who may be allergic to other antibiotics or those with mixed infections caused by both aerobic and anaerobic bacteria. It is often used as an alternative to other carbapenem antibiotics like imipenem and meropenem, which have been associated with seizures and other side effects.
In terms of its availability, ertapenem is listed on Medicare prescription drug plans, typically on Tier 4, which generally has higher associated costs. It is also marketed by Merck under the brand name Invanz. However, it is important to note that individual plans may vary, and formulary information can change. Therefore, it is recommended to contact the applicable plan provider for the most current information regarding ertapenem's availability.
Mayo Clinic Jacksonville: Medicare Coverage and Acceptance
You may want to see also
Explore related products
It is available as an injection for intravenous or intramuscular use in adults and children
Ertapenem is a penem antibacterial medication that treats moderate to severe bacterial infections in adults and children (3 months of age and older). It is available as an injection for intravenous or intramuscular use. When administered intravenously, the drug is slowly infused over at least 30 minutes once or twice a day for up to 14 days. Intramuscular injections can be given once or twice a day for up to 7 days.
The use of ertapenem injections may be indicated for adults requiring the prophylaxis of surgical site infection following elective colorectal surgery. It is also used to treat various infections in adults and children, including complicated intra-abdominal, skin, and skin structure infections, community-acquired pneumonia, and complicated urinary tract infections.
It is important to note that ertapenem injections should not be mixed or co-infused with other medications. Additionally, adverse reactions such as diarrhea, nausea, headache, and infused vein complications have been observed in patients treated with ertapenem injections. Caution should be exercised when administering the injection intramuscularly to avoid injecting it into a blood vessel.
Ertapenem injections can be administered in a hospital setting or at home. When used at home, it is crucial to follow the directions on the prescription label carefully and maintain proper storage and disposal of the medication. Patients should be educated on how to use the medication, and any questions or concerns should be addressed with their healthcare provider.
Insurance Companies: Hospital Scam Partners?
You may want to see also
Common adverse reactions include diarrhoea, nausea, headaches, and infused vein complications
Ertapenem is a carbapenem antibiotic used to treat infections caused by certain bacteria. It is available as an injection for intravenous or intramuscular use. It is typically administered by a healthcare provider in a hospital or clinic.
Common adverse reactions to ertapenem include diarrhoea, nausea, headaches, and infused vein complications. Diarrhoea is a notable side effect, and severe cases may indicate a serious problem. Clostridioides difficile-associated diarrhoea can range from mild to fatal colitis. Patients should be cautious and consult a doctor if diarrhoea occurs. Nausea is another common adverse reaction, and some patients may experience headaches.
In addition to these symptoms, infused vein complications are also common. Caution should be taken to avoid inadvertent injection into a blood vessel. Furthermore, ertapenem may cause serious hypersensitivity reactions, including anaphylaxis, which requires immediate medical attention. Seizures and other central nervous system adverse events have been reported during treatment, particularly in patients with a history of seizures or neurological conditions.
Ertapenem is listed on Tier 4 of the Medicare prescription drug formulary, which generally corresponds to higher prices. However, individual plans may vary, and formulary information can change.
Understanding Hospital Doctor Payment Structures
You may want to see also
It is listed on Tier 4 of the Medicare prescription drug formulary, which can impact affordability
Medicare prescription drug plans typically list ertapenem on Tier 4 of their formulary. A formulary is a list of covered prescription drugs under a healthcare plan. The formulary is usually divided into tiers or levels of coverage based on the type or usage of the medication. Each tier has a defined out-of-pocket cost that the patient must pay before receiving the drug. Generally, the higher the tier, the more you have to pay for the medication. Most plans have 5 tiers.
Tier 1 typically includes low-cost generic and/or brand-name drugs. Tier 2 includes higher-cost generic and brand-name drugs. Tier 3 includes high-cost, mostly brand-name drugs that may have generic or brand-name alternatives in Tiers 1 or 2. Tier 4, where ertapenem is listed, includes the highest-cost, mostly brand-name drugs. Tier 5 includes the highest-cost medicines.
Ertapenem is a carbapenem antibiotic used to treat some infections caused by susceptible bacteria. It is administered via injection and can be used to treat moderate to severe infections such as complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, and complicated urinary tract infections. It can also be used to prevent surgical site infection following elective colorectal surgery.
The cost of ertapenem under Medicare can vary depending on the coverage stage. In the Deductible stage, patients may be responsible for the full cost of the drug. After satisfying the deductible, patients enter the Post-Deductible stage, where they pay a copay and the plan covers the rest of the drug cost. In the Donut Hole stage, there is a temporary limit to what Medicare will cover, so patients may pay more for the drug. In the Post-Donut Hole stage, Medicare should cover most of the drug's cost.
A Beginner's Guide to Playing Two Point Hospital
You may want to see also
Its usage may promote cross-resistance to other carbapenems, so caution is advised
Ertapenem is a carbapenem antibiotic used to treat bacterial infections. It is available as a powder for solution and is administered via injection, either intravenously or intramuscularly.
While ertapenem is an effective treatment option, its usage may promote cross-resistance to other carbapenems. This means that bacteria that develop resistance to ertapenem may also become resistant to other antibiotics in the same class, known as carbapenems. This is a cause for concern as it could limit the effectiveness of these antibiotics in treating infections.
Several studies have investigated the potential impact of ertapenem use on the development of carbapenem-resistant bacteria. Some studies suggest that ertapenem use may not significantly increase carbapenem-resistant P. aeruginosa rates. For instance, a scoping review by Zhanel et al. (2007) found that ertapenem use was not associated with increased resistance rates in the majority of studies included in their review. Similarly, a study by Cook et al. (2011) showed that introducing ertapenem to a hospital formulary led to a reduction in fluoroquinolone use and improved susceptibility of Pseudomonas aeruginosa to group 2 carbapenems.
However, there are also studies indicating a potential link between ertapenem use and increased carbapenem resistance. Lim et al. (2013) observed a negative impact on carbapenem susceptibility, even when there was no change in Group 2 carbapenem consumption. Other studies have found that while ertapenem use may not directly increase resistance to Group 2 carbapenems, higher consumption of Group 2 carbapenems in combination with ertapenem use can lead to increased resistance rates.
Given the potential for ertapenem to promote cross-resistance to other carbapenems, caution is advised when using this antibiotic. It is crucial to ensure that ertapenem is only used when necessary and that alternative treatment options are considered to prevent the development of antibiotic-resistant bacteria. Additionally, hospitals and healthcare providers should carefully monitor antibiotic usage and resistance patterns to identify any potential impacts on carbapenem susceptibility.
The Impact of Rural Hospital Shutdowns on Urban Areas
You may want to see also
Frequently asked questions
Adding ertapenem to a hospital formulary has been found to be an effective antimicrobial management program tool. It has been associated with a decrease in the usage of other broad-spectrum antibiotics, which can result in increased susceptibility to those agents.
The addition of ertapenem to a hospital formulary can have cost savings and clinical utility. It can also help improve antimicrobial stewardship and reduce antibiotic pressure.
There is a concern that widespread usage of ertapenem may promote cross-resistance to other carbapenems. Additionally, there are limitations to the studies conducted on this topic, such as the issue of using proportion versus incidence as the main outcome.
